MIM
MGNX icon

MetLife Investment Management’s MacroGenics MGNX Stock Holding History

MetLife Investment Management’s Portfolio MGNX Stock Details MGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-7,666
Closed -$9.74K – 2892
2025
Q1 		$9.74K Sell
7,666
-32,003
-81% -$83.6K ﹤0.01% 2768
2024
Q4 		$129K Buy
39,669
+24,576
+163% +$88.5K ﹤0.01% 2512
2024
Q3 		$49.7K Sell
15,093
-20,458
-58% -$79.7K ﹤0.01% 2756
2024
Q2 		$151K Buy
35,551
+2,372
+7% +$23.1K ﹤0.01% 2408
2024
Q1 		$488K Hold
33,179
– – ﹤0.01% 1689
2023
Q4 		$319K Hold
33,179
– – ﹤0.01% 1955
2023
Q3 		$155K Hold
33,179
– – ﹤0.01% 2343
2023
Q2 		$178K Hold
33,179
– – ﹤0.01% 2349
2023
Q1 		$238K Hold
33,179
– – ﹤0.01% 2116
2022
Q4 		$223K Hold
33,179
– – ﹤0.01% 2191
2022
Q3 		$115K Buy
33,179
+28,444
+601% +$109K ﹤0.01% 2616
2022
Q2 		$14K Sell
4,735
-28,591
-86% -$150K ﹤0.01% 2849
2022
Q1 		$294K Buy
33,326
+12,267
+58% +$135K ﹤0.01% 2109
2021
Q4 		$338K Hold
21,059
– – ﹤0.01% 1731
2021
Q3 		$441K Hold
21,059
– – ﹤0.01% 1591
2021
Q2 		$566K Hold
21,059
– – 0.01% 1495
2021
Q1 		$671K Sell
21,059
-1,415
-6% -$34.4K 0.01% 1360
2020
Q4 		$514K Hold
22,474
– – ﹤0.01% 1480
2020
Q3 		$566K Hold
22,474
– – 0.01% 1302
2020
Q2 		$627K Hold
22,474
– – 0.01% 1254
2020
Q1 		$131K Hold
22,474
– – ﹤0.01% 1934
2019
Q4 		$245K Hold
22,474
– – ﹤0.01% 1873
2019
Q3 		$287K Hold
22,474
– – ﹤0.01% 1733
2019
Q2 		$381K Buy
22,474
+3,813
+20% +$65.5K ﹤0.01% 1639
2019
Q1 		$336K Hold
18,661
– – ﹤0.01% 1693
2018
Q4 		$237K Hold
18,661
– – ﹤0.01% 1813
2018
Q3 		$400K Hold
18,661
– – ﹤0.01% 1673
2018
Q2 		$385K Buy
18,661
+3,858
+26% +$86.9K ﹤0.01% 1570
2018
Q1 		$372K Hold
14,803
– – ﹤0.01% 1554
2017
Q4 		$281K Buy
+14,803
New +$276K ﹤0.01% 1749

Other funds holding MGNX

BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

MetLife Investment Management's MGNX Position: Q2 2025 in Review

MetLife Investment Management sold out of MacroGenics (MGNX) in Q2 2025, closing a stake of 7,666 shares — an estimated $9.74K sold.

MetLife Investment Management first reported a position in MGNX in Q4 2017 and held it in 30 quarters. The position peaked at $671K in Q1 2021. 112 funds tracked by Wall St. Rank hold MGNX as of Q2 2025.

  • MetLife Investment Management reported no remaining MacroGenics position as of Q2 2025 after selling out during the quarter.
  • MetLife Investment Management sold 7,666 MacroGenics shares in Q2 2025, an estimated $9.74K.
  • MetLife Investment Management first reported a position in MacroGenics in Q4 2017 and held it in 30 quarters.
  • MetLife Investment Management's MacroGenics position peaked at $671K in Q1 2021.
  • 112 funds tracked by Wall St. Rank held MacroGenics as of Q2 2025.

Based on MetLife Investment Management's 13F filing for Q2 2025, filed 13 Aug 2025.